Welcome to N4 Pharma
We’re N4 Pharma, a specialist pharmaceutical company developing a novel silica nanoparticle delivery system for vaccines and therapeutics for licensing to pharmaceutical and biotech partners. This nanoparticle has the potential to help commercialise cancer immunotherapy drugs and improve the effectiveness of viral vaccines.
Watch our video animation below to see Nuvec® in action:
Nuvec® is a unique, non-viral adjuvant delivery system that has the potential to revolutionise vaccines and cancer treatments. It’s currently in the pre-clinical phase and you can download our whitepaper to read all about its mode of action, plus watch our Nuvec® animation!
Latest news and updates
The data – evidence based results
As a result of recently completed initial testing in vitro on loaded Nuvec® with two generic siRNA probes, N4 Pharma has created an infographic outlining the key results and detailing how Nuvec® works to deliver [...]
Article: Deagglomeration of DNA nanomedicine carriers using controlled ultrasonication
Ultrasound sonication is a well-established mechanism for the deagglomeration of particle materials in dispersion. In this recently published paper, the National Physical Laboratory investigates the deagglomeration of Nuvec® silica particles with and without the presence [...]
Poster Presentation: Nuvec® as a gene therapy platform in oncology
In collaboration with Nanomerics Ltd, N4 Pharma has released the results of a recent study assessing the potential of Nuvec® , a non-viral nanoparticle delivery system consisting of poly(ethylenimine) coated silica particles, as a gene [...]